1. Show article details.

    BRIEF-Harpoon Therapeutics Reports Changes To Board Of Directors

    Reuters – 8:58 AM ET 07/02/2020

    Harpoon Therapeutics Inc (HARP): * HARPOON THERAPEUTICS ANNOUNCES CHANGES TO BOARD OF DIRECTORS. * HARPOON THERAPEUTICS (HARP) - FOLLOWING THESE CHANGES, HARPOON'S BOARD WILL BE COMPOSED OF NINE DIRECTORS Source text for Eikon: Further company coverage:

  2. Show article details.

    Harpoon Therapeutics Announces Changes to Board of Directors

    GlobeNewswire – 7:30 AM ET 07/02/2020

    Joanne Viney, Ph.D., brings expertise as an immunologist and veteran biotech executive to the board Drs.

  3. Show article details.

    Harpoon Therapeutics Updates Information for its Participation in Two Upcoming Virtual Conferences

    GlobeNewswire – 7:30 AM ET 06/17/2020

    Harpoon Therapeutics, Inc. (HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced new information regarding its participation in two upcoming investor virtual conferences.

  4. Show article details.

    Harpoon Therapeutics to Participate in Two Upcoming Virtual Conferences

    GlobeNewswire – 7:30 AM ET 06/11/2020

    Harpoon Therapeutics, Inc. (HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Gerald McMahon, Ph.D., President and Chief Executive Officer, will participate in two upcoming virtual investor conferences: A live audio webcast of the fireside chats will be available in the Investors section of Harpoon Therapeutics’ website at www.harpoontx.com...

  5. Show article details.

    BRIEF-Harpoon Therapeutics Presents Interim Phase 1 Data From An Ongoing Dose Escalation Trial For The Psma-Targeting Tritac® Hpn424

    Reuters – 8:34 AM ET 05/29/2020

    Harpoon Therapeutics Inc (HARP): * HARPOON THERAPEUTICS PRESENTS INTERIM PHASE 1 DATA FROM AN ONGOING DOSE ESCALATION TRIAL FOR THE PSMA-TARGETING TRITAC® HPN424 AT THE ASCO20 VIRTUAL SCIENTIFIC PROGRAM. * HARPOON THERAPEUTICS (HARP) - INITIAL SAFETY DATA SHOWED HPN424 GENERALLY WELL-TOLERATED, & CYTOKINE-RELATED ADVERSE EVENTS HAVE BEEN TRANSIENT & MANAGEABLE.

  6. Show article details.

    Harpoon Therapeutics Presents Interim Phase 1 Data from an Ongoing Dose Escalation Trial for the PSMA-targeting TriTAC® HPN424 at the ASCO20 Virtual Scientific Program

    GlobeNewswire – 8:00 AM ET 05/29/2020

    SOUTH SAN FRANCISCO, Calif., May 29, 2020 -- Harpoon Therapeutics, Inc. (HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today presented interim data from the ongoing dose-escalation portion of a Phase 1 trial for HPN424 in patients with metastatic castration-resistant prostate cancer at the American Society of Clinical Oncology 2020 Virtual Scientific Program.

  7. Show article details.

    BRIEF-Harpoon Therapeutics To Present Interim Clinical Data For Tritac At ASCO20 Virtual Scientific Program

    Reuters – 7:39 AM ET 05/22/2020

    Harpoon Therapeutics Inc (HARP): * HARPOON THERAPEUTICS TO PRESENT INTERIM CLINICAL DATA FOR TRITAC® HPN424 AT THE ASCO20 VIRTUAL SCIENTIFIC PROGRAM Source text for Eikon: Further company coverage:

  8. Show article details.

    Harpoon Therapeutics to Present Interim Clinical Data for TriTAC® HPN424 at the ASCO20 Virtual Scientific Program

    GlobeNewswire – 7:30 AM ET 05/22/2020

    Harpoon Therapeutics, Inc. (HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced today that interim Phase 1 data for HPN424 for prostate cancer will be presented at the American Society of Clinical Oncology 2020 Virtual Scientific Program on May 29, 2020.

  9. Show article details.

    Harpoon Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update

    GlobeNewswire – 4:05 PM ET 05/06/2020

    SOUTH SAN FRANCISCO, Calif., May 06, 2020 -- Harpoon Therapeutics, Inc. (HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today reported financial results for the first quarter ended March 31, 2020 and provided a corporate update.

  10. Show article details.

    BRIEF-Harpoon Therapeutics Doses First Patient With HPN217 For Multiple Myeloma

    Reuters – 7:19 AM ET 04/27/2020

    Harpoon Therapeutics Inc (HARP): * HARPOON THERAPEUTICS DOSES FIRST PATIENT WITH HPN217, A BCMA TARGETING TRITAC, FOR MULTIPLE MYELOMA Source text for Eikon: Further company coverage:

  11. Show article details.

    Harpoon Therapeutics Doses First Patient with HPN217, a BCMA Targeting TriTAC, for Multiple Myeloma

    GlobeNewswire – 6:30 AM ET 04/27/2020

    Harpoon Therapeutics, Inc. (HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that the first patient has been dosed with HPN217 in a Phase 1/2 clinical trial focused on relapsed, refractory multiple myeloma.

  12. Show article details.

    Harpoon Therapeutics Appoints Two New Members to Its Board of Directors

    GlobeNewswire – 7:30 AM ET 04/01/2020

    Harpoon Therapeutics, Inc. (HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that it has appointed Andrew R. Robbins and Joseph S. Bailes, M.D., to its Board of Directors.

  13. Show article details.

    Harpoon Therapeutics Reports Fourth Quarter 2019 Financial Results and Provides Corporate Update

    GlobeNewswire – 4:05 PM ET 03/12/2020

    SOUTH SAN FRANCISCO, Calif., March 12, 2020 -- Harpoon Therapeutics, Inc. (HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today reported financial results for the fourth quarter and full year ended December 31, 2019 and provided a corporate update.

  14. Show article details.

    Harpoon Therapeutics to Report Fourth Quarter 2019 Financial Results and Provide Corporate Update

    GlobeNewswire – 7:30 AM ET 03/05/2020

    Harpoon Therapeutics, Inc. (HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced today that it will report fourth quarter and full year 2019 financial results and provide a corporate update on Thursday, March 12, 2020.

  15. Show article details.

    Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences

    GlobeNewswire – 7:30 AM ET 02/20/2020

    Harpoon Therapeutics, Inc. (HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Gerald McMahon, Ph.D., President and Chief Executive Officer, will participate in two upcoming investor conferences: A live audio webcast of the fireside chat and presentation will be available in the Investors section of Harpoon Therapeutics’ website at www.harpo...

Page:

Today's and Upcoming Events

  • Aug
    03

    HARP to announce Q2 earnings (Unconfirmed)

Past Events (last 90 days)

  • May
    06

    HARP announced Q1 earnings.

Data provided by Thomson Reuters © 2020

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.